mitomycin has been researched along with Leukoma in 59 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the safety and efficacy of 5 seconds of mitomycin-C (MMC) application during photorefractive keratectomy (PRK) for low myopia." | 9.17 | Short-time mitomycin-C application during photorefractive keratectomy in patients with low myopia. ( Almasi-Nasrabadi, M; Eslani, M; Ramezanzadeh, M; Rezazadeh, P; Shojaei, A; Soleyman-Jahi, S, 2013) |
| "To study the effect of prophylactic application of mitomycin-C on haze formation in photorefractive keratectomy (PRK) for high myopia." | 9.11 | Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy in high myopia: a prospective clinical study. ( Fotouhi, A; Hashemi, H; Kheiltash, A; Taheri, SM, 2004) |
| "This review details the current understanding of the mechanism of action and corneal effects of mitomycin C (MMC) for prophylactic prevention of stromal fibrosis after photorefractive keratectomy (PRK), and includes discussion of available information on dosage and exposure time recommended for MMC during PRK." | 9.05 | Biological effects of mitomycin C on late corneal haze stromal fibrosis following PRK. ( Carlos de Oliveira, R; Wilson, SE, 2020) |
| "To evaluate the safety and efficacy of mitomycin C (MMC) in haze formation after ultraviolet A/riboflavin corneal crosslinking (CXL) for progressive keratoconus." | 7.88 | Clinical Study of Mitomycin C in Reducing Haze Formation After Ultraviolet A/Riboflavin Crosslinking for Keratoconus. ( Li, Z; Mu, G; Pu, W; Tao, X; Xie, Y; Xu, H; Xu, L; Xu, Y; Zhu, W, 2018) |
| "To present a case of photorefractive keratectomy (PRK) with adjunctive topical mitomycin C (MMC) in an anisometropic hyperopic patient after penetrating keratoplasty (PKP) for keratoconus." | 7.72 | Hyperopic photorefractive keratectomy with adjunctive topical mitomycin C for refractive error after penetrating keratoplasty for keratoconus. ( Donnenfeld, ED; Perry, HD; Solomon, R; Stein, J; Thimons, J, 2004) |
| " However, for moderate myopia and shallow depth, low dosing appears to be equally effective." | 5.35 | Comparison of standard (0.02%) and low dose (0.002%) mitomycin C in the prevention of corneal haze following surface ablation for myopia. ( Krueger, RR; Thornton, I; Xu, M, 2008) |
| "To evaluate the safety and efficacy of 5 seconds of mitomycin-C (MMC) application during photorefractive keratectomy (PRK) for low myopia." | 5.17 | Short-time mitomycin-C application during photorefractive keratectomy in patients with low myopia. ( Almasi-Nasrabadi, M; Eslani, M; Ramezanzadeh, M; Rezazadeh, P; Shojaei, A; Soleyman-Jahi, S, 2013) |
| "To compare 1-year follow-up results of photorefractive keratectomy (PRK) with mitomycin C (MMC) and laser in situ keratomileusis (LASIK) for custom correction of myopia." | 5.14 | One-year outcomes of a bilateral randomised prospective clinical trial comparing PRK with mitomycin C and LASIK. ( Campos, M; Wallau, AD, 2009) |
| "To evaluate the anti-haze effect and visual outcome after intraoperative mitomycin C (MMC) use during photorefractive keratectomy (PRK) in myopia or myopic astigmatism patients." | 5.12 | Mitomycin C for the prevention of corneal haze in photorefractive keratectomy: a meta-analysis and trial sequential analysis. ( Chang, YM; Chien, KH; Lee, CH; Liang, CM; Weng, TH, 2021) |
| "To study the effect of prophylactic application of mitomycin-C on haze formation in photorefractive keratectomy (PRK) for high myopia." | 5.11 | Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy in high myopia: a prospective clinical study. ( Fotouhi, A; Hashemi, H; Kheiltash, A; Taheri, SM, 2004) |
| "To evaluate the results of the prophylactic use of mitomycin-C to inhibit haze formation after excimer laser photorefractive keratectomy (PRK) for medium and high myopia in eyes that were not good candidates for laser in situ keratomileusis (LASIK)." | 5.10 | Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy. ( Carones, F; Scandola, E; Vacchini, L; Vigo, L, 2002) |
| "This review details the current understanding of the mechanism of action and corneal effects of mitomycin C (MMC) for prophylactic prevention of stromal fibrosis after photorefractive keratectomy (PRK), and includes discussion of available information on dosage and exposure time recommended for MMC during PRK." | 5.05 | Biological effects of mitomycin C on late corneal haze stromal fibrosis following PRK. ( Carlos de Oliveira, R; Wilson, SE, 2020) |
| "To evaluate the safety and efficacy of mitomycin C (MMC) in haze formation after ultraviolet A/riboflavin corneal crosslinking (CXL) for progressive keratoconus." | 3.88 | Clinical Study of Mitomycin C in Reducing Haze Formation After Ultraviolet A/Riboflavin Crosslinking for Keratoconus. ( Li, Z; Mu, G; Pu, W; Tao, X; Xie, Y; Xu, H; Xu, L; Xu, Y; Zhu, W, 2018) |
| "To assess visual results and compare methods of measuring central corneal thickness (CCT) and corneal opacity thickness (COT) in patients with corneal opacities induced by epidemic keratoconjunctivitis (EKC) and treated with phototherapeutic keratectomy (PTK) using low-dose mitomycin C (MMC)." | 3.77 | Phototherapeutic keratectomy for the treatment of corneal opacities after epidemic keratoconjunctivitis. ( Allemann, N; Campos, M; Ferraz, CA; Hazarbassanov, RM; Yamazaki, ES, 2011) |
| "Two patients experienced decreased visual acuity in 1 eye arising from elevated corneal opacity about 12 months after uneventful LASEK with intraoperative mitomycin C application." | 3.77 | Recurrent corneal hypertrophic scar after laser-assisted subepithelial keratectomy with mitomycin C treatment. ( Kim, DY; Kim, JH; Kim, JY; Kim, MJ; Tchah, H, 2011) |
| "To evaluate the effect of mitomycin C (MMC) on the exacerbation of corneal opacity that occurs in patients with granular corneal dystrophy type II (GCD II) after refractive corneal surface ablation." | 3.76 | Mitomycin C does not inhibit exacerbation of granular corneal dystrophy type II induced by refractive surface ablation. ( Cho, HS; Choi, SI; Ha, BJ; Kim, EK; Kim, TI; Lee, DH; Stulting, RD, 2010) |
| "To retrospectively assess risk factors other than high myopia for corneal haze in patients who had conventional photorefractive keratectomy (PRK) without mitomycin-C (MMC)." | 3.74 | Astigmatism: risk factor for postoperative corneal haze in conventional myopic photorefractive keratectomy. ( Brunstetter, T; Rogers, S; Sheridan, MV; Thomas, KE, 2008) |
| "To present a case of photorefractive keratectomy (PRK) with adjunctive topical mitomycin C (MMC) in an anisometropic hyperopic patient after penetrating keratoplasty (PKP) for keratoconus." | 3.72 | Hyperopic photorefractive keratectomy with adjunctive topical mitomycin C for refractive error after penetrating keratoplasty for keratoconus. ( Donnenfeld, ED; Perry, HD; Solomon, R; Stein, J; Thimons, J, 2004) |
| "This could explain the recurrences after surgical removal." | 2.82 | [Surgical removal of Salzmann's nodules using intraoperative mitomycin C]. ( Böhringer, D; Eberwein, P; Maier, P; Reinhard, T; Widmer, D, 2016) |
| " New findings regarding the penetration of MMC to the endothelium and into the aqueous humor may lead surgeons to reassess appropriate dosing and patient selection when the drug is used for surgery." | 2.46 | Use of mitomycin-C for phototherapeutic keratectomy and photorefractive keratectomy surgery. ( Shah, RA; Wilson, SE, 2010) |
| " Furthermore, SAHA dosing did not compromise corneal endothelial phenotype, density, or function in rabbit eyes, whereas MMC application did (P < ." | 1.46 | Efficacy and Safety Comparison Between Suberoylanilide Hydroxamic Acid and Mitomycin C in Reducing the Risk of Corneal Haze After PRK Treatment In Vivo. ( Anumanthan, G; Gupta, S; Hamm, CW; Hesemann, NP; Mohan, RR; Sharma, A; Waggoner, M, 2017) |
| "To evaluate the visual outcomes, recurrence patterns, safety, and efficacy of excimer laser phototherapeutic keratectomy (PTK) in conjunction with mitomycin C (MMC) for corneal macular and granular diystrophies." | 1.43 | Excimer laser phototherapeutic keratectomy in conjunction with mitomycin C in corneal macular and granular dystrophies. ( Bilgihan, K; Cubuk, MO; Eroglu, HY; Yuksel, E, 2016) |
| "Mitomycin C was applied immediately after laser ablation." | 1.35 | Mitomycin C in photorefractive keratectomy. ( Gimbel, HV; Kaye, GB; Shalaby, A, 2009) |
| " However, for moderate myopia and shallow depth, low dosing appears to be equally effective." | 1.35 | Comparison of standard (0.02%) and low dose (0.002%) mitomycin C in the prevention of corneal haze following surface ablation for myopia. ( Krueger, RR; Thornton, I; Xu, M, 2008) |
| "Mitomycin C treatment induces apoptosis of keratocytes and myofibroblasts, but the predominate effect in inhibiting or treating haze appears to be at the level of blocked replication of keratocytes or other progenitor cells of myofibroblasts." | 1.33 | Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits. ( Gupta, PC; Mohan, RR; Netto, MV; Sharma, A; Sinha, S; Wilson, SE, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.39) | 18.2507 |
| 2000's | 30 (50.85) | 29.6817 |
| 2010's | 22 (37.29) | 24.3611 |
| 2020's | 5 (8.47) | 2.80 |
| Authors | Studies |
|---|---|
| Charpentier, S | 1 |
| Keilani, C | 1 |
| Maréchal, M | 1 |
| Friang, C | 1 |
| De Faria, A | 1 |
| Froussart-Maille, F | 1 |
| Delbarre, M | 1 |
| Carlos de Oliveira, R | 1 |
| Wilson, SE | 4 |
| Sudanaboina, P | 1 |
| Murthy, SI | 1 |
| Rathi, VM | 1 |
| Chang, YM | 1 |
| Liang, CM | 1 |
| Weng, TH | 1 |
| Chien, KH | 1 |
| Lee, CH | 1 |
| Sanchez-Avila, RM | 1 |
| Uribe-Badillo, EE | 1 |
| Sanz, JF | 1 |
| Muruzabal, F | 1 |
| Jurado, N | 1 |
| Alfonso-Bartolozzi, B | 1 |
| Alfonso, JF | 1 |
| Baamonde, B | 1 |
| Anitua, E | 1 |
| Merayo-Lloves, J | 1 |
| Kaiserman, I | 1 |
| Sadi, N | 1 |
| Mimouni, M | 1 |
| Sela, T | 1 |
| Munzer, G | 1 |
| Levartovsky, S | 1 |
| Xu, L | 1 |
| Tao, X | 1 |
| Li, Z | 1 |
| Xu, Y | 1 |
| Zhu, W | 1 |
| Xu, H | 1 |
| Pu, W | 1 |
| Xie, Y | 1 |
| Mu, G | 1 |
| Anumanthan, G | 1 |
| Sharma, A | 2 |
| Waggoner, M | 1 |
| Hamm, CW | 1 |
| Gupta, S | 1 |
| Hesemann, NP | 1 |
| Mohan, RR | 2 |
| Hofmeister, EM | 2 |
| Bishop, FM | 2 |
| Kaupp, SE | 2 |
| Schallhorn, SC | 2 |
| Leccisotti, A | 2 |
| Fields, SV | 1 |
| Yuksel, E | 1 |
| Cubuk, MO | 1 |
| Eroglu, HY | 1 |
| Bilgihan, K | 1 |
| Böhringer, D | 1 |
| Widmer, D | 1 |
| Eberwein, P | 1 |
| Maier, P | 1 |
| Reinhard, T | 1 |
| Thomas, KE | 1 |
| Brunstetter, T | 1 |
| Rogers, S | 1 |
| Sheridan, MV | 1 |
| Shalaby, A | 1 |
| Kaye, GB | 1 |
| Gimbel, HV | 1 |
| Salomao, MQ | 1 |
| Ma, JJ | 1 |
| Tseng, SS | 1 |
| Yarascavitch, BA | 1 |
| Wallau, AD | 1 |
| Campos, M | 2 |
| Kim, ST | 1 |
| Koh, JW | 1 |
| Yoon, GJ | 1 |
| Yang, SW | 1 |
| Virasch, VV | 1 |
| Majmudar, PA | 3 |
| Epstein, RJ | 3 |
| Vaidya, NS | 1 |
| Dennis, RF | 3 |
| Hongyok, T | 1 |
| Kim, A | 1 |
| Jun, AS | 1 |
| Ladas, JG | 1 |
| Chuck, RS | 1 |
| Ha, BJ | 1 |
| Kim, TI | 2 |
| Choi, SI | 1 |
| Stulting, RD | 1 |
| Lee, DH | 1 |
| Cho, HS | 1 |
| Kim, EK | 1 |
| Shah, RA | 1 |
| Liu, A | 1 |
| Manche, EE | 1 |
| Khakshoor, H | 1 |
| Zarei-Ghanavati, M | 1 |
| Saffarian, L | 1 |
| Yamazaki, ES | 1 |
| Ferraz, CA | 1 |
| Hazarbassanov, RM | 1 |
| Allemann, N | 1 |
| Sher, NA | 1 |
| Golben, MP | 1 |
| Bond, W | 1 |
| Trattler, WB | 1 |
| Kim, JH | 1 |
| Kim, MJ | 1 |
| Kim, DY | 1 |
| Kim, JY | 1 |
| Tchah, H | 2 |
| De Benito-Llopis, L | 1 |
| Teus, MA | 1 |
| Drake-Casanova, P | 1 |
| Yulish, M | 1 |
| Beiran, I | 1 |
| Miller, B | 1 |
| Pikkel, J | 1 |
| Gomes, BA | 1 |
| Smadja, D | 1 |
| Espana, EM | 1 |
| Ahn, ES | 1 |
| Netto, MV | 3 |
| Santhiago, MR | 1 |
| Shojaei, A | 1 |
| Ramezanzadeh, M | 1 |
| Soleyman-Jahi, S | 1 |
| Almasi-Nasrabadi, M | 1 |
| Rezazadeh, P | 1 |
| Eslani, M | 1 |
| Carones, F | 1 |
| Vigo, L | 1 |
| Scandola, E | 1 |
| Vacchini, L | 1 |
| Maust, HA | 1 |
| Raber, IM | 1 |
| Mirza, MA | 1 |
| Qazi, MA | 2 |
| Pepose, JS | 2 |
| Lai, YH | 1 |
| Wang, HZ | 1 |
| Lin, CP | 1 |
| Chang, SJ | 1 |
| Hashemi, H | 1 |
| Taheri, SM | 1 |
| Fotouhi, A | 1 |
| Kheiltash, A | 1 |
| Solomon, R | 1 |
| Donnenfeld, ED | 1 |
| Thimons, J | 1 |
| Stein, J | 1 |
| Perry, HD | 1 |
| Gambato, C | 2 |
| Ghirlando, A | 2 |
| Moretto, E | 1 |
| Busato, F | 1 |
| Midena, E | 2 |
| Kervick, G | 1 |
| Kottler, UB | 1 |
| Dick, HB | 1 |
| Lee, SY | 1 |
| Pak, JH | 1 |
| Kook, MS | 1 |
| Kymionis, GD | 1 |
| Pallikaris, IG | 1 |
| Sinha, S | 1 |
| Gupta, PC | 1 |
| Johnson, TW | 1 |
| Chalita, MR | 1 |
| Krueger, RR | 3 |
| Nassaralla, BA | 1 |
| McLeod, SD | 1 |
| Nassaralla, JJ | 1 |
| Thornton, I | 2 |
| Puri, A | 1 |
| Xu, M | 2 |
| Goldsberry, DH | 1 |
| Epstein, RH | 1 |
| Holley, G | 1 |
| Edelhauser, HF | 1 |
| Miotto, S | 1 |
| Cortese, M | 1 |
| Salvi, R | 1 |
| Gamaly, TO | 1 |
| El Danasoury, A | 1 |
| El Maghraby, A | 1 |
| Nakano, EM | 1 |
| Bains, HS | 1 |
| Hirai, FE | 1 |
| Portellinha, W | 1 |
| Oliveira, M | 1 |
| Nakano, K | 1 |
| Farid, M | 1 |
| Morishige, N | 1 |
| Lam, L | 1 |
| Wahlert, A | 1 |
| Steinert, RF | 1 |
| Jester, JV | 1 |
| Zacharia, PT | 1 |
| Harrison, DA | 1 |
| Wheeler, DT | 1 |
| Mullaney, PB | 1 |
| Selleck, C | 1 |
| Al-Awad, A | 1 |
| Al-Mesfer, S | 1 |
| Zwaan, J | 1 |
| Raviv, T | 1 |
| Winkler von Mohrenfels, C | 1 |
| Hermann, W | 1 |
| Gabler, B | 1 |
| Müller, M | 1 |
| Marshall, J | 1 |
| Lohmann, CP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phototherapeutic Keratectomy With Mitomycin C in Adenoviral Infiltrates[NCT00492245] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Active, not recruiting | |||
| Two Years Follow up of Corneal Cor Cross-linking and Refractive Surface Ablation in Patients With Asymmetric Corneal Topography[NCT02943967] | 44 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Anterior Stromal Changes After PRK by Using Intraoperative Mitomicin C.[NCT00599950] | Phase 4 | 10 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Epi-LASIK : A Confocal Microscopy Analysis of the Corneal Epithelium and Anterior Stroma.[NCT00599690] | 10 participants (Actual) | Interventional | 2006-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for mitomycin and Leukoma
| Article | Year |
|---|---|
Corneal haze post photorefractive keratectomy.
Topics: Cornea; Corneal Opacity; Humans; Lasers, Excimer; Mitomycin; Photorefractive Keratectomy | 2021 |
Biological effects of mitomycin C on late corneal haze stromal fibrosis following PRK.
Topics: Alkylating Agents; Corneal Opacity; Corneal Stroma; Fibrosis; Humans; Lasers, Excimer; Mitomycin; My | 2020 |
Mitomycin C for the prevention of corneal haze in photorefractive keratectomy: a meta-analysis and trial sequential analysis.
Topics: Corneal Opacity; Cross-Linking Reagents; Humans; Mitomycin; Myopia; Photorefractive Keratectomy; Pos | 2021 |
Corneal molecular and cellular biology update for the refractive surgeon.
Topics: Alkylating Agents; Apoptosis; Cornea; Corneal Opacity; Corneal Surgery, Laser; Humans; Lasers, Excim | 2009 |
Use of mitomycin-C for phototherapeutic keratectomy and photorefractive keratectomy surgery.
Topics: Alkylating Agents; Animals; Astigmatism; Combined Modality Therapy; Corneal Opacity; Humans; Hyperop | 2010 |
[Mitomycin C in refractive corneal surface surgery with the excimer laser: first experience and review of the literature].
Topics: Adult; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Corneal Opacity; Humans; Intracellular S | 2005 |
13 trials available for mitomycin and Leukoma
| Article | Year |
|---|---|
Randomized dose-response analysis of mitomycin-C to prevent haze after photorefractive keratectomy for high myopia.
Topics: Adult; Alkylating Agents; Cell Count; Corneal Endothelial Cell Loss; Corneal Opacity; Dose-Response | 2013 |
[Surgical removal of Salzmann's nodules using intraoperative mitomycin C].
Topics: Adult; Aged; Combined Modality Therapy; Corneal Opacity; Follow-Up Studies; Humans; Longitudinal Stu | 2016 |
Mitomycin-C in hyperopic photorefractive keratectomy.
Topics: Administration, Topical; Adult; Alkylating Agents; Astigmatism; Cell Count; Corneal Opacity; Corneal | 2009 |
One-year outcomes of a bilateral randomised prospective clinical trial comparing PRK with mitomycin C and LASIK.
Topics: Adult; Biomechanical Phenomena; Combined Modality Therapy; Contrast Sensitivity; Cornea; Corneal Opa | 2009 |
[Effect of mitomycin C on corneal regrowth after laser-assisted sub-epithelial keratectomy (LASEK)].
Topics: Adult; Cell Division; Corneal Opacity; Female; Fibroblasts; Growth Inhibitors; Humans; Intraoperativ | 2011 |
Ascorbate prophylaxis with mitomycin-C for corneal haze after laser-assisted sub-epithelial keratectomy.
Topics: Adolescent; Adult; Antioxidants; Ascorbic Acid; Astigmatism; Cornea; Corneal Opacity; Drug Therapy, | 2012 |
Short-time mitomycin-C application during photorefractive keratectomy in patients with low myopia.
Topics: Adult; Alkylating Agents; Cell Count; Cornea; Corneal Opacity; Double-Blind Method; Endothelium, Cor | 2013 |
Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy.
Topics: Administration, Topical; Adult; Antibiotics, Antineoplastic; Cornea; Corneal Opacity; Double-Blind M | 2002 |
Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy in high myopia: a prospective clinical study.
Topics: Adult; Antibiotics, Antineoplastic; Corneal Opacity; Humans; Lasers, Excimer; Middle Aged; Mitomycin | 2004 |
Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes.
Topics: Administration, Topical; Adult; Antibiotics, Antineoplastic; Contrast Sensitivity; Cornea; Corneal O | 2005 |
Long-term effects on corneal keratocytes of mitomycin C during photorefractive keratectomy: a randomized contralateral eye confocal microscopy study.
Topics: Administration, Topical; Adult; Cell Count; Cornea; Corneal Opacity; Double-Blind Method; Female; Hu | 2007 |
A prospective, randomized, contralateral eye comparison of epithelial laser in situ keratomileusis and photorefractive keratectomy in eyes prone to haze.
Topics: Adult; Corneal Opacity; Epithelium, Corneal; Female; Humans; Keratomileusis, Laser In Situ; Lasers, | 2007 |
Comparison of laser epithelial keratomileusis with and without mitomycin C for wavefront customized surface ablations.
Topics: Adult; Cell Count; Contrast Sensitivity; Cornea; Corneal Opacity; Diagnostic Techniques, Ophthalmolo | 2007 |
40 other studies available for mitomycin and Leukoma
| Article | Year |
|---|---|
Excimer laser phototherapeutic keratectomy with mitomycin C application to treat haze after myopic photorefractive keratectomy.
Topics: Alkylating Agents; Corneal Opacity; Humans; Lasers, Excimer; Mitomycin; Myopia; Photorefractive Kera | 2020 |
Plasma rich in growth factors versus Mitomycin C in photorefractive keratectomy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Blood Transfusion, Autologous; Corneal Opacity; Female; Hu | 2021 |
Corneal Breakthrough Haze After Photorefractive Keratectomy With Mitomycin C: Incidence and Risk Factors.
Topics: Adult; Alkylating Agents; Corneal Opacity; Female; Humans; Hyperopia; Incidence; Lasers, Excimer; Ma | 2017 |
Clinical Study of Mitomycin C in Reducing Haze Formation After Ultraviolet A/Riboflavin Crosslinking for Keratoconus.
Topics: Adolescent; Adult; Corneal Opacity; Cross-Linking Reagents; Female; Humans; Keratoconus; Male; Mitom | 2018 |
Efficacy and Safety Comparison Between Suberoylanilide Hydroxamic Acid and Mitomycin C in Reducing the Risk of Corneal Haze After PRK Treatment In Vivo.
Topics: Alkylating Agents; Animals; Apoptosis; Cornea; Corneal Opacity; Disease Models, Animal; Fluorescent | 2017 |
Reply: To PMID 23830559.
Topics: Alkylating Agents; Corneal Opacity; Female; Humans; Lasers, Excimer; Male; Mitomycin; Myopia; Photor | 2014 |
Mitomycin-C in photorefractive keratectomy.
Topics: Alkylating Agents; Corneal Opacity; Female; Humans; Lasers, Excimer; Male; Mitomycin; Myopia; Photor | 2014 |
Excimer laser phototherapeutic keratectomy in conjunction with mitomycin C in corneal macular and granular dystrophies.
Topics: Adult; Alkylating Agents; Corneal Dystrophies, Hereditary; Corneal Opacity; Female; Follow-Up Studie | 2016 |
Astigmatism: risk factor for postoperative corneal haze in conventional myopic photorefractive keratectomy.
Topics: Adult; Alkylating Agents; Astigmatism; Corneal Opacity; Female; Humans; Lasers, Excimer; Male; Middl | 2008 |
Mitomycin C in photorefractive keratectomy.
Topics: Alkylating Agents; Combined Modality Therapy; Cornea; Corneal Opacity; Humans; Lasers, Excimer; Mito | 2009 |
Anterior segment optical coherence tomography for transepithelial phototherapeutic keratectomy in central corneal stromal scarring.
Topics: Anterior Eye Segment; Cicatrix; Corneal Diseases; Corneal Opacity; Corneal Stroma; Epithelium, Corne | 2009 |
Clinical outcomes of epi-LASIK: 1-year results of on- and off-flap procedures with and without mitomycin-C.
Topics: Adult; Corneal Opacity; Corneal Topography; Female; Humans; Keratomileusis, Laser In Situ; Male; Mit | 2010 |
Reduced application time for prophylactic mitomycin C in photorefractive keratectomy.
Topics: Adult; Alkylating Agents; Corneal Opacity; Female; Humans; Lasers, Excimer; Male; Mitomycin; Myopia; | 2010 |
Phototherapeutic keratectomy with mitomycin C after Descemet stripping automated endothelial keratoplasty.
Topics: Aged, 80 and over; Combined Modality Therapy; Corneal Opacity; Descemet Stripping Endothelial Kerato | 2010 |
Mitomycin C does not inhibit exacerbation of granular corneal dystrophy type II induced by refractive surface ablation.
Topics: Adult; Alkylating Agents; Corneal Dystrophies, Hereditary; Corneal Opacity; Female; Humans; Keratect | 2010 |
Visually significant haze after retreatment with photorefractive keratectomy with mitomycin-C following laser in situ keratomileusis.
Topics: Adult; Alkylating Agents; Combined Modality Therapy; Corneal Opacity; Female; Humans; Keratomileusis | 2010 |
Mechanical superficial keratectomy for corneal haze after photorefractive keratectomy with mitomycin C and extended wear contact lens.
Topics: Administration, Topical; Adult; Contact Lenses, Extended-Wear; Cornea; Corneal Opacity; Female; Foll | 2011 |
Phototherapeutic keratectomy for the treatment of corneal opacities after epidemic keratoconjunctivitis.
Topics: Adenovirus Infections, Human; Adolescent; Adult; Aged; Conjunctivitis, Viral; Contrast Sensitivity; | 2011 |
A retrospective review of photorefractive keratectomy to enhance earlier radial keratotomy.
Topics: Adult; Aged; Corneal Opacity; Eyeglasses; Female; Humans; Keratotomy, Radial; Male; Middle Aged; Mit | 2011 |
Recurrent corneal hypertrophic scar after laser-assisted subepithelial keratectomy with mitomycin C treatment.
Topics: Adult; Alkylating Agents; Cicatrix, Hypertrophic; Corneal Opacity; Debridement; Female; Humans; Kera | 2011 |
Very late-onset corneal scar triggered by trauma after photorefractive keratectomy.
Topics: Alkylating Agents; Cornea; Corneal Injuries; Corneal Opacity; Eye Injuries; Female; Glucocorticoids; | 2012 |
Peripheral hypertrophic subepithelial corneal degeneration.
Topics: Adult; Androstadienes; Anti-Allergic Agents; Antibiotics, Antineoplastic; Corneal Dystrophies, Hered | 2003 |
Treatment of dense subepithelial corneal haze after laser-assisted subepithelial keratectomy.
Topics: Adult; Corneal Opacity; Corneal Topography; Debridement; Epithelium, Corneal; Humans; Keratomileusis | 2004 |
Mitomycin C alters corneal stromal wound healing and corneal haze in rabbits after argon-fluoride excimer laser photorefractive keratectomy.
Topics: Animals; Apoptosis; Argon; Corneal Opacity; Corneal Stroma; Fluorides; Instillation, Drug; Lasers, E | 2004 |
Hyperopic photorefractive keratectomy with adjunctive topical mitomycin C for refractive error after penetrating keratoplasty for keratoconus.
Topics: Administration, Topical; Adult; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Corneal Opacity | 2004 |
Subepithelial scarring after laser-assisted subepithelial keratectomy.
Topics: Corneal Opacity; Corneal Topography; Debridement; Epithelium, Corneal; Humans; Keratectomy, Subepith | 2005 |
Mitomycin C, ceramide, and 5-fluorouracil inhibit corneal haze and apoptosis after PRK.
Topics: Animals; Apoptosis; Ceramides; Cornea; Corneal Opacity; Fluorouracil; Lasers, Excimer; Mitomycin; Ph | 2006 |
Mitomycin C in highly myopic eyes.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Cornea; Corneal Opacity; Humans; Lasers, Excim | 2006 |
Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits.
Topics: Animals; Apoptosis; Cell Count; Cell Proliferation; Cornea; Corneal Opacity; Disease Models, Animal; | 2006 |
Development of late-onset subepithelial corneal haze after laser-assisted subepithelial keratectomy with prophylactic intraoperative mitomycin-C Case report and literature review.
Topics: Adult; Alkylating Agents; Combined Modality Therapy; Corneal Opacity; Debridement; Epithelium, Corne | 2006 |
Corneal haze following PRK with mitomycin C as a retreatment versus prophylactic use in the contralateral eye.
Topics: Adult; Antibiotics, Antineoplastic; Combined Modality Therapy; Corneal Opacity; Female; Humans; Lase | 2007 |
Prophylactic mitomycin C to inhibit corneal haze after photorefractive keratectomy for residual myopia following radial keratotomy.
Topics: Adult; Alkylating Agents; Cell Count; Corneal Opacity; Endothelium, Corneal; Female; Humans; Keratot | 2007 |
Low-dose mitomycin C as a prophylaxis for corneal haze in myopic surface ablation.
Topics: Adolescent; Adult; Cornea; Corneal Opacity; Female; Follow-Up Studies; Humans; Keratectomy, Subepith | 2007 |
Effect of mitomycin C on the corneal endothelium when used for corneal subepithelial haze prophylaxis following photorefractive keratectomy.
Topics: Cell Count; Corneal Opacity; Endothelium, Corneal; Humans; Lasers, Excimer; Mitomycin; Myopia; Nucle | 2007 |
Comparison of standard (0.02%) and low dose (0.002%) mitomycin C in the prevention of corneal haze following surface ablation for myopia.
Topics: Adult; Alkylating Agents; Corneal Opacity; Humans; Lasers, Excimer; Mitomycin; Myopia; Photorefracti | 2008 |
Detection of corneal fibrosis by imaging second harmonic-generated signals in rabbit corneas treated with mitomycin C after excimer laser surface ablation.
Topics: Alkylating Agents; Animals; Combined Modality Therapy; Cornea; Corneal Opacity; Fibrillar Collagens; | 2008 |
Penetrating keratoplasty with a valved glaucoma drainage implant for congenital glaucoma and corneal scarring secondary to hydrops.
Topics: Administration, Topical; Anterior Chamber; Antibiotics, Antineoplastic; Corneal Edema; Corneal Opaci | 1998 |
Combined trabeculotomy and trabeculectomy as an initial procedure in uncomplicated congenital glaucoma.
Topics: Chemotherapy, Adjuvant; Child, Preschool; Corneal Opacity; Female; Glaucoma; Humans; Infant; Infant, | 1999 |
Mytomycin-C for post-PRK corneal haze.
Topics: Alkylating Agents; Corneal Opacity; Humans; Lasers, Excimer; Mitomycin; Ophthalmic Solutions; Photor | 2000 |
[Topical Mitomycin C for the prophylaxis of recurrent haze after excimer laser photorefractive keratectomy (PRK) - a pilotstudy of 5 patients].
Topics: Adult; Corneal Opacity; Female; Follow-Up Studies; Humans; Lasers, Excimer; Male; Mitomycin; Ophthal | 2001 |